Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.
Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, Surrey LF, Russo P, Sleight A, Schiffrin E, Gabay C, Goldbach-Mansky R, Behrens EM. Canna SW, et al. Among authors: schiffrin e. J Allergy Clin Immunol. 2017 May;139(5):1698-1701. doi: 10.1016/j.jaci.2016.10.022. Epub 2016 Nov 19. J Allergy Clin Immunol. 2017. PMID: 27876626 Free PMC article.
Reply.
Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, Surrey LF, Russo P, Sleight A, Schiffrin E, Gabay C, Goldbach-Mansky R, Behrens EM. Canna SW, et al. Among authors: schiffrin e. J Allergy Clin Immunol. 2017 Jul;140(1):316-317. doi: 10.1016/j.jaci.2017.03.016. Epub 2017 Apr 29. J Allergy Clin Immunol. 2017. PMID: 28460789 No abstract available.
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.
Yasin S, Solomon K, Canna SW, Girard-Guyonvarc'h C, Gabay C, Schiffrin E, Sleight A, Grom AA, Schulert GS. Yasin S, et al. Among authors: schiffrin e. Rheumatology (Oxford). 2020 Feb 1;59(2):442-445. doi: 10.1093/rheumatology/kez284. Rheumatology (Oxford). 2020. PMID: 31359055 Free PMC article. No abstract available.
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ. Gabay C, et al. Among authors: schiffrin ej. Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22. Ann Rheum Dis. 2018. PMID: 29472362 Free PMC article. Clinical Trial.
Elevated serum levels of free interleukin-18 in adult-onset Still's disease.
Girard C, Rech J, Brown M, Allali D, Roux-Lombard P, Spertini F, Schiffrin EJ, Schett G, Manger B, Bas S, Del Val G, Gabay C. Girard C, et al. Rheumatology (Oxford). 2016 Dec;55(12):2237-2247. doi: 10.1093/rheumatology/kew300. Epub 2016 Sep 10. Rheumatology (Oxford). 2016. PMID: 27616144
Probiotics and immune response.
Blum S, Haller D, Pfeifer A, Schiffrin EJ. Blum S, et al. Clin Rev Allergy Immunol. 2002 Jun;22(3):287-309. doi: 10.1007/s12016-002-0013-y. Clin Rev Allergy Immunol. 2002. PMID: 12043386 Review. No abstract available.
728 results